Free Trial

Thermo Fisher Scientific (TMO) Stock Forecast & Price Target

Thermo Fisher Scientific logo
$512.86 +3.74 (+0.73%)
(As of 11/20/2024 ET)

Thermo Fisher Scientific - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
18

Based on 22 Wall Street analysts who have issued ratings for Thermo Fisher Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 4 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for TMO.

Consensus Price Target

$649.33
26.61% Upside
According to the 22 analysts' twelve-month price targets for Thermo Fisher Scientific, the average price target is $649.33. The highest price target for TMO is $718.00, while the lowest price target for TMO is $575.00. The average price target represents a forecasted upside of 26.61% from the current price of $512.86.
Get the Latest News and Ratings for TMO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Thermo Fisher Scientific and its competitors.

Sign Up

TMO Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
17 Buy rating(s)
13 Buy rating(s)
14 Buy rating(s)
Hold
4 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$649.33$656.00$618.94$593.94
Forecasted Upside26.61% Upside11.90% Upside2.12% Upside21.83% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

TMO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Thermo Fisher Scientific Stock vs. The Competition

TypeThermo Fisher ScientificMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside26.61% Upside26,931.53% Upside9.83% Upside
News Sentiment Rating
Positive News

See Recent TMO News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/24/2024Sanford C. Bernstein
3 of 5 stars
 Lower TargetMarket Perform ➝ Market Perform$625.00 ➝ $620.00+10.17%
10/24/2024Royal Bank of Canada
4 of 5 stars
 Lower TargetOutperform ➝ Outperform$767.00 ➝ $718.00+27.51%
10/24/2024Stifel Nicolaus
4 of 5 stars
 Lower TargetBuy ➝ Buy$680.00 ➝ $665.00+17.72%
10/24/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$630.00 ➝ $620.00+9.38%
10/24/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Couillard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$670.00 ➝ $660.00+16.46%
10/24/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$632.00 ➝ $622.00+7.89%
10/23/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$620.00 ➝ $610.00+6.63%
10/22/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$656.00 ➝ $686.00+16.92%
10/22/2024Bernstein Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$565.00 ➝ $625.00+6.30%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$680.00+13.74%
10/1/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$680.00+9.93%
9/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$650.00 ➝ $670.00+9.13%
9/20/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$655.00 ➝ $680.00+10.95%
9/16/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Leonard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/16/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$600.00 ➝ $675.00+10.44%
7/25/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$650.00 ➝ $660.00+9.56%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Buy$600.00 ➝ $650.00+14.44%
4/30/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$660.00 ➝ $670.00+17.13%
4/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$600.00 ➝ $610.00+6.54%
4/10/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$550.00 ➝ $640.00+10.94%
3/18/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$620.00+6.70%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$575.00+15.58%
10/26/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Sector Weight
7/13/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$620.00+17.89%
2/2/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$620.00 ➝ $630.00+7.26%
2/2/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$690.00 ➝ $711.00+21.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:11 AM ET.


Should I Buy Thermo Fisher Scientific Stock? TMO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 6, 2024. Please send any questions or comments about these Thermo Fisher Scientific pros and cons to contact@marketbeat.com.

Thermo Fisher Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Thermo Fisher Scientific Inc.:

  • Thermo Fisher Scientific Inc. has a strong track record of consistent earnings growth, with an expected EPS of 21.72 for the current fiscal year. This indicates financial stability and potential for future returns.
  • The company has a high percentage of institutional ownership at 89.23%, which signifies confidence from large investors and stability in the stock.
  • Recent insider selling activities totaling $14,094,292 may indicate that insiders believe the stock is overvalued, potentially prompting a correction in the stock price.
  • Thermo Fisher Scientific Inc. offers a quarterly dividend of $0.39 per share, with a dividend payout ratio of 10.01%. This provides investors with a steady income stream.
  • Analysts have given Thermo Fisher Scientific Inc. positive ratings, with an average rating of "Moderate Buy" and a consensus price target of $647.78, suggesting potential for stock price appreciation.

Thermo Fisher Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Thermo Fisher Scientific Inc. for these reasons:

  • Insiders have sold a significant number of shares worth $14,094,292 over the last three months, which could be interpreted as a lack of confidence in the company's future performance.
  • The current stock price of Thermo Fisher Scientific Inc. may be inflated due to the high institutional ownership and positive analyst ratings, potentially leading to a price correction.
  • Thermo Fisher Scientific Inc.'s dividend yield of 0.26% may not be attractive to income-seeking investors compared to other dividend-paying stocks.
  • While the company has a strong earnings outlook, any unexpected changes in the market or industry conditions could impact its ability to meet earnings expectations.
  • Investing in Thermo Fisher Scientific Inc. carries market risk, as the stock price can be influenced by various external factors beyond the company's control.

TMO Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Thermo Fisher Scientific is $649.33, with a high forecast of $718.00 and a low forecast of $575.00.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Thermo Fisher Scientific in the last twelve months. There are currently 4 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TMO shares.

According to analysts, Thermo Fisher Scientific's stock has a predicted upside of 26.61% based on their 12-month stock forecasts.

Over the previous 90 days, Thermo Fisher Scientific's stock had 1 upgrade by analysts.

Analysts like Thermo Fisher Scientific more than other "medical" companies. The consensus rating score for Thermo Fisher Scientific is 2.86 while the average consensus rating score for "medical" companies is 2.80. Learn more on how TMO compares to other companies.


This page (NYSE:TMO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners